Interleukin-16 and peptide derivatives as immunomodulatory therapy in allergic lung disease

Bibliography

• CRUIKSHANK W, CENTER DM:Modulation of lymphocyte migration by human lymphokines. II. Purification of a lymphotactic factor (LCF). Immunol (1982) 128:2569–2574.
   Google Scholar
• •Initial description of LCF/IL-16: one of the first described T cell-specific chemoattractants.
   Google Scholar
• LABERGE S, CRUIKSHANK WW, KORNFELD H, CENTER DM: Histamine-induced secretion of lymphocyte chemoattractant factor from CD8+ T cells is independent of transcription and translation. Evidence for constitutive protein synthesis and storage.' Immunol (1995) 155:2902–2910.
   Google Scholar
• RUMSAENG V, CRUIKSHANK WW, FOSTER B et al.: Human mast cells produce the CD4+ T lymphocyte chemoattractant factor, IL-16. .1 Immunol (1997) 159:2904–2910.
   Google Scholar
• LIM KG, WAN HC, BOZZA PT et al: Human eosinophils elaborate the lymphocyte chemoattractants. IL-16 (lymphocyte chemoattractant factor) and RANTES. I Immunol (1996) 156:2566–2570.
   PubMed Web of Science ®Google Scholar
• SCIAKY D, BRAZER W, CENTER DM,CRUIKSHANK WW, SMITH TJ: Cultured human fibroblasts express constitutive IL-16 mRNA: cytokine induction of active IL-16 protein synthesis through a caspase-3- dependent mechanism. j. Immunol (2000) 164:3806–3814.
   PubMed Web of Science ®Google Scholar
• LABERGE S, ERNST P, GHAFFAR 0 et al.: Increased expression of interleukin-16 in bronchial mucosa of subjects with atopic asthma. Am. J. Respic Cell MM. Biol. (1997) 17:193–202.
   Google Scholar
• •In situ and irnmunohistochemical localisation of IL-16 to epithelium in asthma.
   Google Scholar
• KORNFELD H, CRUIKSHANK WW: Prospects for IL-16 in the treatment of AIDS. Expert Opin. Biol. The]: (2001) 1:425–432.
   Google Scholar
• BUSSE WW, LEMANSKE RF JR:Asthma. N Engl. J. Med. (2001) 344:350–362.
   PubMed Web of Science ®Google Scholar
• •Detailed review of asthma pathophysiology with applicable clinical and basic science.
   Google Scholar
• MOSMANN TR, CHERWINSKI H, BOND MW, GIEDLIN MA, COFFMAN RL: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol (1986) 136:2348–2357.
   Google Scholar
• •Landmark set of three articles [9-11] that set the foundation for the paradigm of reciprocally inhibited differentiation of CD4+ T cells into Thl and Th2.
   Google Scholar
• CHER DJ, MOSMANN TR: Two types ofmurine helper T cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones. Immunol (1987) 138:3688–3694.
   Google Scholar
• CHERWINSKI HM, SCHUMACHER JH, BROWN KD, MOSMANN TR: Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Thl and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. J. Exp. Med. (1987) 166:1229–1244.
   Google Scholar
• DEL PRETE GE DE CARLI M, MASTROMAURO C et al: Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. J. Clin. Invest (1991) 88:346–350.
   PubMed Web of Science ®Google Scholar
• YAMAMURA M, UYEMURA K, DEANS RI et al.: Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science (1991) 254:277–279.
   PubMed Web of Science ®Google Scholar
• SZABO SJ, KIM ST, COSTA GL, ZHANG X, FATHMAN CG, GLIMCHER LH: A novel transcription factor, T-bet, directs Thl lineage commitment. Cell (2000) 100:655–669.
   PubMed Web of Science ®Google Scholar
• •Molecular mechanisms [14-16] at transcriptional level of reciprocal inhibition of Thl and Th2 cell differentiation and cytokine profiles.
   Google Scholar
• ZHENG W, FLAVELL RA: The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell (1997) 89:587–596.
   PubMed Web of Science ®Google Scholar
• HO IC, LO D, GLIMCHER LH: c-mafpromotes T helper cell type 2 (Th2) and attenuates Thl differentiation by both interleukin 4-dependent and -independent mechanisms. I Exp. Med. (1998) 188:1859–1866.
   PubMed Web of Science ®Google Scholar
• TEMANN UA, GEBA GP, RANKIN IA, FLAVELL RA: Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. J. Exp. Med. (1998) 188:1307–1320.
   PubMed Web of Science ®Google Scholar
• ZHU Z, HOMER RI, WANG Z et al: Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. Clin. Invest. (1999) 103:779–788.
   Google Scholar
• BARNES PJ: Cytokine-directed therapies for the treatment of chronic airway diseases. Cytokine Growth Factor Rev. (2003) 14:511–522.
   PubMed Web of Science ®Google Scholar
• AKDIS CA, KUSSEBI F, PULENDRAN B et al.: Inhibition of T helper 2-type responses, IgE production and eosinophilia by synthetic lipopeptides. Ear. I Immunol (2003) 33:2717–2726.
   PubMed Web of Science ®Google Scholar
• •Use of synthetic bacterial wall products to inhibit Th2 responses by 'promoting' Thl environment.
   Google Scholar
• LYNCH EA, HEIJENS CA, HORST NE CENTER DM, CRUIKSHANK WW: Cutting edge: IL-16/CD4 preferentially induces Thl cell migration: requirement of CCR5. Immunol (2003) 171:4965–4968.
   Web of Science ®Google Scholar
• ••Provides mechanistic explanation forIL-16-related downregulation of Th2 responses not related to inhibition of T cell activation.
   Google Scholar
• KIM HS: Assignment of human interleukin 16 (IL16) to chromosome 15q26.3 by radiation hybrid mapping. Cytogenet. Cell Genet. (1999) 84:93.
   PubMedGoogle Scholar
• BANNERT N, KURTH R, BAIER M: The gene encoding mouse interleukin-16 consists of seven exons and maps to chromosome 7 D2-D3. Immunogenetics (1999) 49:704–706.
   PubMed Web of Science ®Google Scholar
• KURSCHNER C, YUZAKI M: Neuronal interleukin-16 (NIL-16): a dual function PDZ domain protein. I Neurosci. (1999) 19:7770–7780.
   Google Scholar
• •Description of longer IL-16 precursor located in CNS.
   Google Scholar
• BANNERT N, VOLLHARDT K, ASOMUDDINOV B et al.: PDZ Domain-mediated interaction of interleukin-16 precursor proteins with myosin phosphatase targeting subunits. J. Biol. Chem. (2003) 278:42190–42199.
   PubMed Web of Science ®Google Scholar
• BANNERT N, AVOTS A, BAIER M, SERFLING E, KURTH R: GA-binding protein factors, in concert with the coactivator CREB binding protein/p300, control the induction of the interleukin 16
   Google Scholar
• •• promoter in T lymphocytes. Proc. Natl. Acad. Sci. USA (1999) 96:1541–1546.
   Google Scholar
• •Characterisation of proximal IL-16 promoter regulation in the immortalised Jurkat T cell line.
   Google Scholar
• CHUPP GL, WRIGHT EA, WU D et al: Tissue and T cell distribution of precursor and mature IL-16. j. Immunol (1998) 161:3114–3119.
   PubMed Web of Science ®Google Scholar
• KASER A, DUNZENDORFER S, OFFNER FA et al: A role for IL-16 in the cross-talk between dendritic cells and T cells. Immunol (1999) 163:3232–3238.
   Web of Science ®Google Scholar
• LABERGE S, CRUIKSHANK WW, BEER DJ, CENTER DM: Secretion of IL-16 (lymphocyte chemoattractant factor) from serotonin- stimulated CD8+ T cells in vitro. Immunol (1996) 156:310–315.
   Web of Science ®Google Scholar
• ZHANG Y, CENTER DM, WU DM et al.: Processing and activation of pro-interleukin-16 by caspase-3../. Biol. Chem. (1998) 273:1144–1149.
   Google Scholar
• MUHLHAHN P, ZWECKSTETTER M, GEORGESCU J et al.: Structure of interleukin 16 resembles a PDZ domain with an occluded peptide binding site. Nat. Struct. Biol. (1998) 5:682–686.
   PubMedGoogle Scholar
• CENTER DM, CRUIKSHANK WW, ZHANG Y: Nuclear pro-IL-16 regulation of T cell proliferation: p27(KIP1)-dependent GO/G1 arrest mediated by inhibition of Skp2 transcription. Immunol. (2004) 172:1654–1660.
   Web of Science ®Google Scholar
• WILSON KC, CRUIKSHANK WW, CENTER DM, ZHANG Y: Prointerleukin-16 contains a functional CcN motif that regulates nuclear localization. Biochemistry (2002) 41:14306–14312.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, KORNFELD H, CRUIKSHANK WW, KIM S, REARDON CC, CENTER DM: Nuclear translocation of the N-terminal prodomain of interleukin-16. Biol. Chem. (2001) 276:1299–1303.
   Web of Science ®Google Scholar
• LIU Y, CRUIKSHANK WW, O'LOUGHLIN T, O'REILLY P, CENTER DM, KORNFELD H: Identification of a CD4 domain required for interleukin-16 binding and lymphocyte activation. J. Biol. Chem. (1999) 274:23387–23395.
   PubMed Web of Science ®Google Scholar
• ••Demonstration that binding site of IL-16on the D4 domain of CD4 maps to the sequence required for CD4 autoaggregation during T cell activation [36].
   Google Scholar
• CRUIKSHANK WW, CENTER DM, NISAR N et al.: Molecular and functional analysis of a lymphocyte chemoattractant factor: association of biologic function with CD4 expression. Proc. Nati Acad. Sci. USA (1994) 91:5109–5113.
   PubMed Web of Science ®Google Scholar
• ••Cloning of LCF/IL-16 and requirementfor CD4 expression in IL-16-mediated T cell responses.
   Google Scholar
• KEANE J, NICOLL J, KIM S et al.: Conservation of structure and function between human and murine IL-16. Immunol (1998) 160:5945–5954.
   Web of Science ®Google Scholar
• BANNERT N, ADLER HS, WERNER A, BAIER M, KURTH R: Molecular cloning and sequence analysis of interleukin 16 from nonhuman primates and from the mouse. Immunogenetics (1998) 47:390–397.
   PubMed Web of Science ®Google Scholar
• MATHY NL, BANNERT N, NORLEY SG, KURTH R: Cutting edge: CD4 is not required for the functional activity of IL-16. J. Immunol. (2000) 164:4429–4432.
   PubMed Web of Science ®Google Scholar
• YANG J, LIU CQ: Interaction between human interleukin-16 and CD4 receptor of HIV-1. Acta Pharmacol Sin. (2000) 21:547–553.
   PubMed Web of Science ®Google Scholar
• KITCHEN SG, LAFORGE S, PATEL VP, KITCHEN CM, MICELI MC, ZACK JA: Activation of CD8 T cells induces expression of CD4, which functions as a chemotactic receptor. Blood (2002) 99:207–212.
   PubMed Web of Science ®Google Scholar
• CRUIKSHANK WW, GREENSTEIN JL, THEODORE AC, CENTER DM: Lymphocyte chemoattractant factor induces CD4-dependent intracytoplasmic signaling in lymphocytes.' Immunol (1991) 146:2928–2934.
   Web of Science ®Google Scholar
• RYAN TC, CRUIKSHANK WW, KORNFELD H, COLLINS TL, CENTER DM: The CD4-associated tyrosine kinase p561ck is required for lymphocyte chemoattractant factor-induced T lymphocyte migration. I. Biol. Chem. (1995) 270:17081–17086.
   Web of Science ®Google Scholar
• PARADA NA, CRUIKSHANK WW, DANIS HL, RYAN TC, CENTER DM: IL-16- and other CD4 ligand-induced migration is dependent upon protein kinase C. Cell. Immunol (1996) 168:100–106.
   PubMed Web of Science ®Google Scholar
• NICOLL J, CRUIKSHANK WW, BRAZER W, LIU Y, CENTER DM, KORNFELD H: Identification of domains in IL-16 critical for biological activity. Immunol (1999) 163: 1827-1832.
   Google Scholar
• ••Identification of 4-amino acid RRKSsequence that mediates bioactivity.
   Google Scholar
• WU H, KWONG PD, HENDRICKSON WA: Dimeric association and segmental variability in the structure of human CD4. Nature (1997) 387:527–530.
   PubMed Web of Science ®Google Scholar
• GRATTON S, HAUGHN L, SEKALY RP, JULIUS M: The extracellular domain of CD4 regulates the initiation of T cell activation. Ma Immunol (2000) 37:213–219.
   PubMed Web of Science ®Google Scholar
• CICALA C, ARTHOS J, RUIZ M et al.: Induction of phosphorylation and intracellular association of CC chemokine receptor 5 and focal adhesion kinase in primary human CD4+ T cells by macrophage-tropic HIV envelope. Immunol (1999) 163:420–426.
   Web of Science ®Google Scholar
• •Demonstration that HIV gp120 can elicit signalling of CD4 and CCR5.
   Google Scholar
• MASHIKIAN MV, RYAN TC, SEMAN A, BRAZER W, CENTER DM, CRUIKSHANK WW: Reciprocal desensitization of CCR5 and CD4 is mediated by IL-16 and macrophage-inflammatory protein-1 beta, respectively. Immunol (1999) 163:3123–3130.
   Web of Science ®Google Scholar
• ••Two articles [49,50] that describeIL-16-mediated chemokine receptor desensitisation and, therefore, regulation of inflammatory cell chemoattraction.
   Google Scholar
• VAN DRENTH C, JENKINS A, LEDWICH L et al.: Desensitization of CXC chemokine receptor 4, mediated by IL-16/CD4, is independent of p561ck enzymatic activity. Immunol (2000) 165:6356–6363.
   Web of Science ®Google Scholar
• STAUDINGER R, PHOGAT SK, XIAO X, WANG X, DIMITROV DS, ZOLLA-PAZNER S: Evidence for CD4-enchanced signaling through the chemokine receptor CCR5. J. Biol. Chem. (2003) 278:10389–10392.
   PubMed Web of Science ®Google Scholar
• WANG X, STAUDINGER R: Interactionof soluble CD4 with the chemokine receptor CCR5. Biochem. Biophys. Res. Commun. (2003) 307:1066–1069.
   PubMed Web of Science ®Google Scholar
• WONG M, UDDIN S, MAJCHRZAK B et al.: Rantes activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells. Biol. Chem. (2001) 276:11427–11431.
   Web of Science ®Google Scholar
• THEODORE AC, CENTER DM, NICOLL J, FINE G, KORNFELD H, CRUIKSHANK WW: CD4 ligand IL-16 inhibits the mixed lymphocyte reaction. Immunol (1996) 157: 1958-1964.
   Google Scholar
• CRUIKSHANK WW, LIM K, THEODORE AC et al: IL-16 inhibition of
   Google Scholar
• CD3-dependent lymphocyte activation and proliferation. J. Inanunol. (1996) 157:5240–5248.
   Google Scholar
• ••Initial detailed description of IL-16-induced T cell anergy in setting of antigen stimulation.
   Google Scholar
• DE BIE JJ, JONKER EH, HENRICKS PA et al.: Exogenous interleukin-16 inhibits antigen-induced airway hyper-reactivity, eosinophilia and Th2-type cytokine production in mice. Clin. Exp. Allergy (2002) 32(11):1651–1658.
   PubMedGoogle Scholar
• ••In vivo characterisations of irnmunomodulatory effect of systemic IL-16 and aerosolised peptide on allergic airway response.
   Google Scholar
• DE BIE JJ, HENRICKS PA, CRUIKSHANK WW, HOFMAN G, NIJKAMP FP, VAN OOSTERHOUT AJ: Effect of interleukin-16-blocking peptide on parameters of allergic asthma in a murine model. Eur.j Pliarmacol (1999) 383:189–196.
   PubMed Web of Science ®Google Scholar
• ••See [56].
   Google Scholar
• BLASCHKE S, SCHULZ H, SCHWARZ G, BLASCHKE V, MULLER GA, REUSS-BORST M: Interleukin 16 expression in relation to disease activity in rheumatoid arthritis. Rlieumatol. (2001) 28:12–21.
   PubMed Web of Science ®Google Scholar
• KEATES AC, CASTAGLIUOLO I, CRUIKSHANK WW et al.: Interleuldn 16 is up-regulated in Crohn's disease and participates in TNBS colitis in mice. Gastroenterology (2000) 119:972–982.
   PubMed Web of Science ®Google Scholar
• CHENG G, ARIMA M, HONDA K et al:Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am. I Respir. Crit. Care Med. (2002) 166:409–416.
   PubMed Web of Science ®Google Scholar
• PINSONNEAULT S, EL BASSAM S, MAZER B, CRUIKSHANK WW, LABERGE S: IL-16 inhibits IL-5 production by antigen-stimulated T cells in atopic subjects. I Allergy Clin. Innnunal. (2001) 107:477–482.
   PubMed Web of Science ®Google Scholar
• CRUIKSHANK WW, LONG A, TARPY RE et al: Early identification of interleukin-16 (lymphocyte chemoattractant factor) and macrophage inflammatory protein 1 alpha (MIP1 alpha) in bronchoalveolar lavage fluid of antigen-challenged asthmatics. Am. Respir. Cell Mol. Biol. (1995) 13:738–747.
   PubMed Web of Science ®Google Scholar
• MASHIKIAN MV, TARPY RE, SAUKKONEN JJ et al.: Identification of IL-16 as the lymphocyte chemotactic activity in the bronchoalveolar lavage fluid of histamine-challenged asthmatic patients. Allergy Clin. Innnunel. (1998) 101:786–792.
   PubMed Web of Science ®Google Scholar
• LABERGE S, PINSONNEAULT S, VARGA EM et al.: Increased expression of IL-16 immunoreactivity in bronchial mucosa after segmental allergen challenge in patients with asthma. I Allergy Clin. Immune]. (2000) 106:293–301.
   PubMed Web of Science ®Google Scholar
• BLEASE K, LEWIS A, RAYMON HK: Emerging treatments for asthma. Expert Opin. Emerg. Drugs (2003) 8:71–81.
   PubMedGoogle Scholar
• CHUNG KF: Individual cytokines contributing to asthma pathophysiology: valid targets for asthma therapy? Curt: Opin. Investig. Drugs (2003) 4:1320–1326.
   Google Scholar
• BORISH LC, NELSON HS, LANZ MJ et al.: Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am. J. Rcpir. Crit. Care Med. (1999) 160:1816–1823.
   Web of Science ®Google Scholar
• BORISH LC, NELSON HS, CORREN J et al.: Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. Allergy Clin. Inanunol. (2001) 107:963–970.
   PubMed Web of Science ®Google Scholar
• FLOOD-PAGE P, MENZIES-GOW A, PHIPPS S et al.: Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J. Clin. Invest (2003) 112:1029–1036.
   PubMed Web of Science ®Google Scholar
• MENZIES-GOW A, FLOOD-PAGE P, SEHMI R et al: Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. I Allergy Clin. Immune]. (2003) 111:714–719.
   PubMed Web of Science ®Google Scholar
• LUKACS NW, BERLIN A, SCHOLS D, SKERLJ RT, BRIDGER GJ: AMD3100, a CxCR4 antagonist, attenuates allergic lung inflammation and airway hyperreactivity. Am. J. Pathol (2002) 160:1353–1360.
   PubMed Web of Science ®Google Scholar